New
Zenome Genetic Test
Zenome Genetic TestRead full post

Bitcoin is a digital money.
Genome is a digital you.

Zenome is a decentralized market
of genomic data and services.

New
Zenome Genetic Test
Zenome Genetic TestRead full post
Need assistance?

ZNA token sale ends in

days
hours
mins
secs
Buy ZNA tokensJoin Whitelist
The first round of public sales is over. The soft cap has been reached. For private purchasing of ZNA-tokens, join the whitelist. You can also make your donation to the Zenome Foundation at these addresses:
Current fundings:
1 125 269 of 3 200 000 ZNA
 soft cap has been reached
Exchange rates:
1 BTC =13560 ZNA
1 ETH =814 ZNA

Welcome to the genomic revolution

— Richard Resnick


Or watch on

Data is a new gold

DaaS - Data as a Service

1
Did you know that
100 million people around the world already have their DNA data.
2
Did you know that
BIG companies are buying this data?
3
Did you know that
23andMe has sold data from 1 million of DNA samples for $130m dollars.
4
Did you know that
Businesses can offer you personalized products based on your DNA test results.
Zenome is a decentralized market of genomic data and services. They buy your data. You buy their services.
Join the ZNA community:

The future is already here.

You have almost missed it. Jump in.

Genomics —
the global industry
of tomorrow

Market size, $B
In 2007 (two years before bitcoin came) a new market has emerged - genomics and you probably do not know about that. This is the next big step in development.

The pros and cons

Genomics unlimited
capabilities

  • Predisposition to diseases
  • Ancestry
  • Nutrition
  • Intolerance and allergy
  • Predisposition to addictions
  • A rough estimate of life span

Genomics threats
 

  • Potential DNA abuse
    (You can be rejected when hiring for predisposition to disease)
  • Closed databases (scientists do not have access)
  • Who owns DNA?
    (Companies use your data as they want after you made the test)

Zenome: how does it work?

Do big companies sell your DNA data? Sell it yourself!
Do you already have 23andMe report? Get reports from other providers without having to send saliva again

User sends genetic samples to an accredited partner laboratory
User receives a text file with his DNA
User uploads the sequence file to Zenome.io platform
User buys genetic services. User sells genetic data.

Zenome platform presentation

Zenome is the world's first platform that creates an unified
market of personal genomic information and services.


Or watch on

Roadmap

The Team

Guys look young due to achievments
in genomics

Alexey Gorbachev
Founder, business
Education:  Moscow State University, department of molecular biology (MSU)
Degree:  Ph.D. in molecular biology and biochemistry
Specialization:  Molecular biologist and Blockchain Enthusiast
Specialist in molecular biology and personal genomics. Alexey has a significant scientific background, expertise in business, and project management. In Zenome Alexey is responsible for the overall vision and development of the business.
Nikolay Kulemin
Founder, bioinformatics
Education:  Moscow Institute of Physics and Technology, department of molecular and biological physics (MIPT)
Degree:  Ph.D. in bioinformatics
Specialization:  Bioinformatist
Specialist in bioinformatics and mathematical biology, has experience of academic research and applied developments in the genome industry. Nikolay is a founder of a company developing new algorithms for genomic analysis.
Vladimir Naumov
Genomic data scientist
Education:  Pirogov Russian National Research Medical University (RNRMU)
Specialization:  Data scientist in human genomics
Bioinformatics and data analysis specialist. ex-CSO at iBinom, bioinformatics scientist at GERO, 8 years in genomics industry. Works on creating pipelines and developing new ways in analysis and visualisations of genomic data.
Sergey Popov
Blockchain developer, cypherpunk
Education:  Moscow Institute of Physics and Technology, department of general and applied physics (MIPT)
Specialization:  Theoretical physics, theoretical informatics and pure mathematics
Distributed systems architect, smart blockchain developer.
Anastasia Gubina
Community manager
Education:  National Research University "Higher School of Economics", department of Political Science (HSE) – 2017, The University of Edinburgh "School of Social and Political Science" – 2016
Degree:  Bachelor in Political Data Analysis
Interests – technology and growth, boxing and foreign languages, humanitarian organizations activity (a volunteer of Russian Red Cross).
Alexey Kuzmenkov
Neuroscientist, Neuromarketing
Education:  Moscow State University, department of bioorganic chemistry (MSU)
Degree:  Ph.D. in biochemistry
Specialization:  Neurochemist
Alexey get natural scientific background and was awarded by the Moscow Government for his research. In 2016 Alexey won the scholarship of the President of the Russian Federation for young scientists. The general interest of Alexey in Zenome is in application of blockchain ecosystem for the biological approaches.

The Advisors

Dmitry Kwon
Zenome advisor
 
Education:  Moscow State University, department of molecular biology (MSU)
Degree:  Ph.D. in molecular biology
Specialization:  Molecular biologist, business development manager
Specialist in molecular genetics. Dmitry has a significant scientific background, expertise genetic analysis technologies, genomic and diagnostic markets, has successful business experience in biotechnology and Dx top intl companies.
Yuri Nikolsky
Advisor in
business development
Education:  Moscow State University, department of genetics (MSU)
Degree:  Doctoral degree in molecular genetics
Specialization:  Businessman and researcher in the field of life sciences
Dr. Nikolsky has 25 years of experience in life sciences, both business and research. Currently, he is CEO of Prosapia Genetics and an associated faculty at George Mason University in Virginia. In 2014-2016, he was CSO/director of Science at the BMT cluster at Skolkovo, the largest innovation fund in Russia. In 2010-2014. Yuri served as Vice President of R&D at Thomson Reuters (TR), a global information company, where he built a scientific consulting group working with major pharmaceutical companies on Big Data management and analysis. In 2003-2010 Dr. Nikolsky was CEO of GeneGo, a systems biology company acquired by Thomson Reuters in 2010. Prior to GeneGo, he was CEO of ChemDiv (San Diego, CA), a drug discovery CRO, turned into a fast growing pharmaceutical company. Dr. Nikolsky also co-founded Integrated Genomics, Inc. (Chicago, IL), a comparative genomics and bioinformatics company and held positions of a Senior Scientist for Thermogen, Inc. (Chicago, IL) and a scientist at the University of Chicago. Dr. Nikolsky holds an MBA degree in finance from the Booth School of Business (the University of Chicago), a Doctoral degree in molecular genetics from VNIIGenetika Graduate School and an MS degree in biology from Lomonosov Moscow State University; both in Moscow, Russia. Dr. Nikolsky’s research interests are in disease research, precision and translational medicine. Dr. Nikolsky authored over 90 research articles, 5 patents and two books on systems biology.
Richard Resnick
Senior advisor
 
Education:  M.B.A. from the MIT Sloan School of Management, an M.S. in Computer Science from Worcester Polytechnic Institute, and a B.S. in Computer Science from the University of Massachusetts at Amherst.
Degree:  M.B.A. from the MIT Sloan School of Management
Specialization:  Entrepreneur, TED Speaker
Mr. Richard Resnick serves as the Chief Executive Officer of GenomeQuest, Inc. Mr. Resnick served as Acting Chief Executive Officer of GenomeQuest, Inc. since September 2010 and Vice President of Software and Professional Services. Mr. Resnick heads up GenomeQuest's product development and professional services organizations. He served as a Vice President of Products and Services at GenomeQuest, Inc. He served as Vice President of Software & Services at GenomeQuest, Inc. He has extensive experience in building and growing innovative, sales-driven technology teams in the software and life science industries. Prior to joining GenomeQuest, he served as Chief Executive Officer of Harmony Line, Inc. Prior to Harmony Line, he spent over a decade in the sequence informatics industry, founding and selling Mosaic Bioinformatics in 1999 to NetGenics, Inc. He served as global bioinformatics software manager for Wyeth, and contributed to the Human Genome Project under Eric Lander at the MIT Whitehead Institute for Biomedical Research. He serves as a Director of GenomeQuest. Mr. Resnick holds an M.B.A. from the MIT Sloan School of Management, an M.S. in Computer Science from Worcester Polytechnic Institute, and a B.S. in Computer Science from the University of Massachusetts at Amherst.
Vadim Pushkarev
Advisor
 
Education:  Moscow State University (MSU), Department of law.
Degree:  Bachelor of law (Commercial Law)
Specialization:  Corporate law, corporate governance, M&A, venture capital investment
Vadim Pushkarev has 17 years of experience in corporate law and corporate governance. He started his legal career in Professional Association of Registrars, Transfer-Agents and Depositories, self-regulated organization of professional participants of Russian stock market.

In 2002 - 2011 Vadim worked in managerial positions in corporate governance and M&A departments of several Russian industrial companies (including RAO UES of Russia and RusHydro, electric power companies with hundreds of thousands of shareholders and hundreds of subsidiaries). Vadim has an experience of project management in billions-dollar-worth M&A deals, reorganizations and capital stock issuances.

Vadim Pushkarev served as a member of Board of directors in several industrial companies.

In 2011 Vadim made a shift in his career, moving into venture capital industry, and now has an experience of angel, seed, Series A investment deals in different industries and jurisdictions.

In 2014 Vadim was a member of the Board of directors of Sight Diagnostics, Israeli company developing computer-vision based solution for screening blood samples for malaria and CBC (complete blood count test).

Currently Vadim is Associate director at Emery Capital, being responsible for development of several internet-related projects.

Vadim Pushkarev is a member of Board of directors in Accent Media Ltd., London-based company developing new generic top level domain “.tickets” - the new space in Internet, which has already seen several blockchain-based projects, building new technologies for safe and fair ticket sales.

In parallel to his business activities Vadim supports several non-for-profit and charitable activities. Vadim is honored blood donor of Russia.

The Partners

Progen
Service Provider
Rosalind
Service Provider
Skoltech
RnD Partner

The future is already here.

You have almost missed it. Jump in.

Follow us:
Zenome Agreement   |  Certification Form
Privacy policy  &  Cookie policy
Or watch on
Or watch on
Scroll down
to learn more